Skip To Main Content
David Wild on Muck Rack

David Wild

Verified
Toronto
As seen in: Citeline, In Vivo, Apple Podcasts, CNN, The New York Times, Color Research & Application, HuffPost, Variety, Billboard, Elsevier, Quartz, Rolling Stone and
I cover the world of pharma and biotech for In Vivo @invivonow, a @Citeline publication. I also play in a Grateful Dead cover band. Please DM with story ideas.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Federated Learning Wave: Part 2, Beyond Proof of Concept

|
By David Wild Verified
| Citeline Verified
The engineering, science and deal-making that will determine whether federated learning transforms biopharma AI or stalls again. Federated learning, José-Tomás Prieto told delegates at the most recent BIO-IT World, is a kind of seat belt – a techno-regulatory mechanism that makes it very difficult to behave badly when you’re accessing very sensitive, sometimes secret, proprietary data.
Open in Who Shared Issue with article?

The Federated Learning Wave: Part 1, The Model Goes to the Data

|
By David Wild Verified
| Citeline Verified
Biopharma Ramps Up Federated Learning for AI Drug Discovery Federated learning promised to crack biopharma's data problem. Four years on, it's finally being built for real. (Shutterstock) Key Takeaways Federated learning - training AI models across multiple companies' data without anyone surrendering proprietary datasets - has moved from proof-of-concept experiment to deployable infrastructure, with Lilly's TuneLab signing up 115 partners in under a year.
Open in Who Shared Issue with article?

Incannex Bets On Psychotherapy As The Missing Ingredient In Psychedelic Medicine

|
By David Wild Verified
| Citeline Verified
As President Trump's executive order on psychedelics reshapes the regulatory landscape, Incannex Healthcare says its insistence on guided psychotherapy – and a real-world clinic to prove the model works – gives it an edge rivals have ceded. (Shutterstock) Key Takeaways The Executive Order helps Incannex even without a breakthrough designation, mainly through faster FDA access and potential rescheduling.
Open in Who Shared Issue with article?
See all 771 licensed articles (808 Total)